Royalty Pharma plc is the largest acquirer of biopharmaceutical royalties. The company owns a portfolio of royalty interests that provide payments tied to sales of biopharmaceutical products. Royalty Pharma earns royalties from more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica for chronic lymphocytic leukemia and other blood cancers, Biogen’s Tysabri for relapsing forms of multiple sclerosis, Vertex’s cystic fibrosis franchise, as well as 10 product candidates in development.